RES treatment maintained the same level of aconitase activity as CTRL (97%; Figure 3(e)) and increased mitochondrial superoxide dismutase (SOD) by 36% compared to the PAH group (Figure 3(g)), which is a direct target of SIRT3. This evidence concerns the gene SIRT3 and pulmonary arterial hypertension.